Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

PAVmed (PAVM) EBITDA (2022 - 2025)

Historic EBITDA for PAVmed (PAVM) over the last 4 years, with Q3 2025 value amounting to -$4.8 million.

  • PAVmed's EBITDA changed N/A to -$4.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$20.2 million, marking a year-over-year change of. This contributed to the annual value of -$44.5 million for FY2024, which is 3533.4% up from last year.
  • According to the latest figures from Q3 2025, PAVmed's EBITDA is -$4.8 million.
  • Over the past 5 years, PAVmed's EBITDA peaked at -$4.7 million during Q2 2025, and registered a low of -$24.6 million during Q4 2022.
  • Moreover, its 4-year median value for EBITDA was -$16.0 million (2023), whereas its average is -$14.8 million.
  • Per our database at Business Quant, PAVmed's EBITDA plummeted by 390.12% in 2023 and then skyrocketed by 6833.91% in 2024.
  • Over the past 4 years, PAVmed's EBITDA (Quarter) stood at -$24.6 million in 2022, then skyrocketed by 33.41% to -$16.4 million in 2023, then soared by 68.34% to -$5.2 million in 2024, then grew by 6.61% to -$4.8 million in 2025.
  • Its EBITDA was -$4.8 million in Q3 2025, compared to -$4.7 million in Q2 2025 and -$5.4 million in Q1 2025.